Compare Ascendis Pharma A/S (ASND) vs iShares Semiconductor ETF (SOXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares Semiconductor ETF — how do they compare? Ascendis Pharma A/S trades at $255.01 (market cap $16.67B), while iShares Semiconductor ETF trades at $551.78. Which is the better fit depends on your goals.
| ASND | SOXX | |
|---|---|---|
Market Cap | $16.67B | — |
Sector | Health | Sector/Thematic |
52-Week High | $277.18 | $655.01 |
52-Week Low | $189.74 | $241.68 |
Enterprise Value | $17.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
SOXX trades at $552.56, up 4.24% with a bullish technical signal from moving averages. The semiconductor ETF faces mixed sentiment as recent news highlights sector rotation away from chips toward software, though major cloud companies' strong earnings support AI infrastructure demand. Technical indicators show neutral oscillators with key resistance at $548.
Outlook remains cautiously optimistic given AI-driven semiconductor demand, but risks include tariff impacts, concentration in 30 stocks, and potential overvaluation after 2026 gains. Institutional buying (Bank of America increased holdings 20.9% in Q1 2026) signals confidence, yet investor caution is warranted amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →
